WHWK Stock — Whitehawk Therapeutics Inc.: Cash, EV, Pipeline

Share price

$4.20

Market cap

$239.4M

Cash

$190.0M

Enterprise value

$49.4M

Balance sheet

Cash	$190.0M
Debt	$0.0M
Net cash	$190.0M
Enterprise value	$49.4M
Basic shares	57.0M shares
Fully diluted shares	70.6M shares
Fully diluted market cap	$296.5M
Cash per share	$3.33

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading WHWK daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 14 - Apr 25	HWK-016, MUCIN-16-targeted ADC	Phase 1	PROC; Platinum Resistant Ovarian Cancer; Endometrial Cancer	—
Nov 12 - Dec 24	HWK-007	Phase 1	Endometrial Cancer; Ovarian Cancer; Ovarian Cancer Metastatic	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

HWK-007

Phase 1 · Active Modality: antibody-drug conjugate (TOP1 inhibitor payload)

Target PTK7

Partnerships WuXi Biologics: exclusive license to ADC assets (Dec 2024); milestones up to $265M development + $540M commercial plus royalties. Hangzhou DAC: CPT113 linker-payload technology

Indications

Non-small cell lung cancer (NSCLC) (Phase 1)
Ovarian cancer (Phase 1)
Endometrial cancer (Phase 1)

Catalysts

— H1 2027

Status note PTK7-directed ADC. IND cleared; Phase 1 HWK-007-101 actively recruiting adults with advanced or metastatic solid tumors refractory to standard therapies.

HWK-016

Phase 1 · Active Modality: antibody-drug conjugate (TOP1 inhibitor payload)

Target MUC16

Partnerships WuXi Biologics: exclusive license to ADC assets (Dec 2024); milestones up to $265M development + $540M commercial plus royalties. Hangzhou DAC: CPT113 linker-payload technology

Indications

Ovarian cancer (Phase 1)
Endometrial cancer (Phase 1)

Catalysts

— H1 2027

Status note MUC16-directed ADC. IND cleared; Phase 1 HWK-016-101 actively recruiting.

HWK-206

Preclinical · Active Modality: antibody-drug conjugate (TOP1 inhibitor payload)

Target SEZ6

Partnerships WuXi Biologics: exclusive license to ADC assets (Dec 2024). Hangzhou DAC: CPT113 linker-payload technology; May 2026 option agreement for up to five additional ADC programs

Indications

Small cell lung cancer (SCLC) (Preclinical)
Neuroendocrine tumors (NETs) (Preclinical)

Catalysts

— mid-2026

Status note Biparatopic SEZ6-directed ADC. IND-enabling studies underway; IND submitted with FDA clearance anticipated mid-2026.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	HWK-016, MUCIN-16-targeted ADC
Lead indication	PROC
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07470853	Phase 1	Recruiting	Sponsor	WHWK	—	PROC; Platinum Resistant Ovarian Cancer; Endometrial Cancer	—
NCT07444814	Phase 1	Recruiting	Sponsor	WHWK	—	Endometrial Cancer; Ovarian Cancer; Ovarian Cancer Metastatic	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Whitehawk Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	3,934,296	-231,704	0.34%	2026-08-14
ADAR1 Capital Management	1,341,394	+1,212,891	0.29%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

WHWK — Whitehawk Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders